Effect of Double Fortification (Iron and Zinc) in Synbiotic Milk to Under 5 Years Stunted Children Growth

Sponsor
Gadjah Mada University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03495401
Collaborator
(none)
100
1
2
8.1
12.3

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the effects of double fortification (iron and zinc) in synbiotic milk (L.plantarum Dad13 and fructooligosaccharides) on under 5 years stunted children growth, gut microbiota composition, blood zinc and hemoglobin level, and cognitive level.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: fortified synbiotic milk
  • Dietary Supplement: non-fortified synbiotic milk
N/A

Detailed Description

This is a parallel, quadruple-blind, randomized controlled trial to determine the effects of double fortification (iron and zinc) in synbiotic milk (containing 7 billion CFU L.plantarum Dad13 and 4 g fructooligosaccharides) on the gut microbiota composition, body height and weight, blood zinc and hemoglobin level, and cognitive level in under 5 years stunted children subjects. The duration of the study is 4 months, including a 2-week pre test and informed consent before randomization of subjects into treatment or control group, a 12-week intervention period, and a 2-week post test after the end of intervention. During the intervention period, subjects will be instructed to take 100 ml of fortified synbiotic milk or non-fortified synbiotic milk per day. They will also be asked to document consumed milk, any unusual symptoms or side effects of treatment. Diet will be monitored via 24-h dietary recalls and SQ-FFQ before and after treatment respectively. Changes in the gut microbiota composition will be determined by measuring bacterial population levels (Bifidobacteria, Lactobacillus, Enterobacteria, Prevotella, and Bacteroides) in stool sampled collected at baseline and 12 weeks by qPCR. Metabolic markers (calprotectin, hemoglobin, and zinc level) will be measured at baseline and 12-weeks in serum and plasma using biochemical and immuno-assay. Changes in the cognitive level, height for age Z-score collected at baseline and 12 weeks using Bayley Scales of Infant Development, 2nd Edition .

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Intervention group given fortified synbiotic milk, control group given non-fortified synbiotic milkIntervention group given fortified synbiotic milk, control group given non-fortified synbiotic milk
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of Double Fortification (Iron and Zinc) in Synbiotic Milk to Under 5 Years Stunted Children Growth : the Efforts to Achieve Target 2 SDGs Utilizing Local Natural Resources
Actual Study Start Date :
Apr 28, 2018
Anticipated Primary Completion Date :
Sep 30, 2018
Anticipated Study Completion Date :
Dec 31, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: fortified synbiotic milk

100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides

Dietary Supplement: fortified synbiotic milk
100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
Other Names:
  • susu synbio (synbio milk) fortified
  • Placebo Comparator: non-fortified synbiotic milk

    100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides

    Dietary Supplement: non-fortified synbiotic milk
    100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
    Other Names:
  • susu synbio (synbio milk) non-fortified
  • Outcome Measures

    Primary Outcome Measures

    1. Changes in Gut Microbiota Associated to Synbiotic Milk Treatment [3 months]

      Stools samples will be collected and analyzed before and after the intervention and compared between groups (Lactobacillus, Bifidobacteria, Bacteroides, Prevotella, and Enterobacteria) using qPCR method.

    Secondary Outcome Measures

    1. Changes in Height per Age Z-score Associated to Synbiotic Milk Treatment [3 months]

      Height data will be collected and analyzed before and after the intervention and compared between groups

    2. Changes in Hemoglobin Level Associated to Synbiotic Milk Treatment [3 months]

      Hemoglobin data will be collected and analyzed before and after the intervention and compared between groups using biochemistry method

    3. Changes in Calprotectin Level Associated to Synbiotic Milk Treatment [3 months]

      Calprotectin data will be collected and analyzed before and after the intervention and compared between groups using immuno-assay method

    4. Changes in Blood Zinc Level Associated to Synbiotic Milk Treatment [3 months]

      Calprotectin data will be collected and analyzed before and after the intervention and compared between groups using Atomic Absorbance Spectrophotometry method

    5. Changes in Cognitive Level Associated to Synbiotic Milk Treatment [3 months]

      Cognitive level will be collected and analyzed before and after the intervention and compared between groups using Bayley Scales of Infant Development, 2nd Edition (BSID). This part of BSID evaluation, which yields a score called the mental development index, evaluates several types of abilities: sensory/perceptual acuities, discriminations, and response; acquisition of object constancy; memory learning and problem solving; vocalization and beginning of verbal communication; basis of abstract thinking; habituation; mental mapping; complex language; and mathematical concept formation. Total score from test will determine mental development index of children : accelerated performance (score ≥85), within normal limit (score 70-84), mildly delayed performance (score 55-69), and significantly delayed performance (score <55).

    6. Changes in Psychomotor Level Associated to Synbiotic Milk Treatment [3 months]

      Psychomotor data will be collected and analyzed before and after the intervention and compared between groups using Bayley Scales of Infant Development, 2nd Edition (BSID). This part of the BSID assesses the degree of body control, large muscle coordination, finer manipulatory skills of the hands and fingers, dynamic movement, postural imitation, and the ability to recognize objects by sense of touch (stereognosis). Total score from test will determine motor development index of children : accelerated performance (score ≥85), within normal limit (score 70-84), mildly delayed performance (score 55-69), and significantly delayed performance (score <55).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    2 Years to 5 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • age between 2 year to 5 years

    • height per age z-score under -2 (stunting)

    • parents sign inform consent form

    Exclusion Criteria:
    • have congenital abnormality

    • lactose intolerant

    • use antibiotic for more than 2 weeks

    • consume micronutrient supplement (especially iron and zinc) in the last 3 months

    • diagnose with chronic diseases and infection that interfere metabolism (i.e. tuberculosis, HIV, autoimmune disease, diabetes mellitus type 1)

    • suffer marasmus and/or kwashiorkor

    • not willing to continue the intervention

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Universitas Gadjah Mada Sleman D.I.Yogyakarta Indonesia 55281

    Sponsors and Collaborators

    • Gadjah Mada University

    Investigators

    • Principal Investigator: Siti Helmyati, DR., Gadjah Mada University
    • Principal Investigator: Lily A. Lestari, DR., Gadjah Mada University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    DR.Siti Helmyati, DCN, M.Kes, DR., Gadjah Mada University
    ClinicalTrials.gov Identifier:
    NCT03495401
    Other Study ID Numbers:
    • KE/FK/0640/EC/2017
    First Posted:
    Apr 12, 2018
    Last Update Posted:
    May 1, 2018
    Last Verified:
    Apr 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 1, 2018